Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Verastem target raised to $6.50 at H.C. Wainwright (1.51)H.C. Wainwright raises their VSTM tgt to $6.50 from $5. They noted that based on results from earlier stage studies in CLL as well as the previously completed Dynamo study in indolent non-Hodgkin's lymphoma, Duo is highly likely to meet its primary PFS endpoint. Furthermore, H.C. Wainwright further discusses that while many investors have doubts regarding duvelisib's commercial outlook in the competitive CLL indication, they believe that, even with less-than-stellar results from Duo, the drug has the potential to capture a material portion of the highly lucrative market for 2nd/3rd-line CLL treatments. Therefore, H.C. Wainwright expects positive results from the Duo study to be a significant catalyst for the co; reiterates Buy.</td> </tr></table>"